Mergers & acquisitions
The deal has Sanofi paying $105 per share in cash.
The announcement sent shares of Juno soaring more than 27 percent in pre-market trading to $86.26.
A look at whether the new tax reform will really spur a M&A spending spree for drugmakers.
Immune Design is a clinical-stage immunotherapy company.
All of the recent problems have caused the company’s largest shareholder to push for a sale.
Analysts feel the company’s profit potential is starting to improve following a year in which its shares fell by more than 21%.
Investors and analysts have given it some thought and mostly think it’s a sensible acquisition.
Chinese interest in the J&J unit comes as the market for diabetes care in China is expected to grow rapidly.
The rumors have caused Juno’s stock to rocket more than 50 percent to $68.80 in premarket trading.
Speculation around a possible bid has mounted in recent months.
PRESS RELEASES